⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670970 | 0.82 | — | — | |
| SCHEMBL11832991 | 0.79 | HRH3 (0.41) | — | |
| SCHEMBL1228572 | 0.77 | HCAR2 (0.37) | — | |
| SCHEMBL17033121 | 0.76 | — | — | |
| SCHEMBL20734524 | 0.76 | GPR84 (0.39) | — | |
| SCHEMBL34847 | 0.73 | — | — | |
| SCHEMBL2028609 | 0.73 | — | — | |
| SCHEMBL26855708 | 0.73 | PTPN1 (0.33) | — | |
| SCHEMBL31413847 | 0.72 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL3643624 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| EP-4630414-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4620528-A2 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4275756-B1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250206726-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2025-06-26 | — | — | US | disclosed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12247020-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| WO-2024121256-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-9382231-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2997023-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2016-03-23 | — | — | EP | disclosed |
| CN-105121418-A | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection | GILEAD SCIENCES INC | 2015-12-02 | — | — | CN | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2014186706-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343030-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-3957480-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1976-05-18 | — | — | US | disclosed |